CNCR vs. ARKG

Last updated Jun 24, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and ARKG (ARK Genomic Revolution Multi-Sector ETF) are both Health & Biotech Equities funds. CNCR is passively managed, while ARKG is actively managed. CNCR charges 0.79%/yr vs 0.75%/yr for ARKG.

Performance

CNCR vs. ARKG - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and ARK Genomic Revolution Multi-Sector ETF (ARKG). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

ARKG

• 1D: -1.07%
• 1M: 17.41%
• YTD: 24.30%
• 6M: 19.48%
• 1Y: 52.71%
• 3Y*: 3.17%
• 5Y*: -16.56%
• 10Y*: 8.67%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. ARKG - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
ARKG ARK Genomic Revolution Multi-Sector ETF	30.99%

CNCR vs. ARKG - Sectors Allocation Comparison

Sectors	CNCR	ARKG
Healthcare	96.6%	99.3%
Financial Services	3.3%	0.5%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

CNCR vs. ARKG — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CNCR

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

ARKG

ARKG Risk / Return Rank: 36
ARKG Sharpe Ratio Rank: 36
ARKG Sortino Ratio Rank: 38
ARKG Omega Ratio Rank: 34
ARKG Calmar Ratio Rank: 40
ARKG Martin Ratio Rank: 32

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. ARKG - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	CNCR	ARKG	Difference
Sharpe ratio: Return per unit of total volatility	—	1.25	—
Sortino ratio: Return per unit of downside risk	—	1.91	—
Omega ratio: Gain probability vs. loss probability	—	1.22	—
Calmar ratio: Return relative to maximum drawdown	—	1.93	—
Martin ratio: Return relative to average drawdown	—	4.58	—

Drawdowns

CNCR vs. ARKG - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum ARKG drawdown of -83.59%. Use the drawdown chart below to compare losses from any high point for CNCR and ARKG.

Drawdown Indicators

	CNCR	ARKG	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-83.59%	+83.59%
Max Drawdown (1Y) Largest decline over 1 year	—	-27.51%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-51.96%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-80.18%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-83.59%	—
Current Drawdown Current decline from peak	0.00%	-67.78%	+67.78%
Average Drawdown Average peak-to-trough decline	0.00%	-36.02%	+36.02%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	11.53%	—

Volatility

Volatility by Period

	CNCR	ARKG	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	15.19%	—
Volatility (6M) Calculated over the trailing 6-month period	—	30.91%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	42.54%	-42.54%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	45.93%	-45.93%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	41.29%	-41.29%

CNCR vs. ARKG - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than ARKG's 0.75% expense ratio.

Dividends

CNCR vs. ARKG - Dividend Comparison

Neither CNCR nor ARKG has paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017
ARKG ARK Genomic Revolution Multi-Sector ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.62%	0.85%	3.14%	0.82%	1.34%
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Which ETF is better, CNCR or ARKG?

On fees, ARKG is cheaper at 0.75% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or ARKG?

ARKG is cheaper with a 0.75% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, CNCR or ARKG?

CNCR and ARKG have nearly identical dividend yields, around 0.00%.

What is the main difference between CNCR and ARKG?

They also come from different issuers: Exchange Traded Concepts and ARK. Their fees differ too: 0.79% for CNCR and 0.75% for ARKG.